PMID- 28415706
OWN - NLM
STAT- MEDLINE
DCOM- 20180326
LR  - 20181113
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 8
IP  - 19
DP  - 2017 May 9
TI  - The role of targeted agents in the adjuvant treatment of colon cancer: a 
      meta-analysis of randomized phase III studies and review.
PG  - 31112-31118
LID - 10.18632/oncotarget.16091 [doi]
AB  - There has been debate as to whether targeted agents have beneficial effect when 
      added to adjuvant chemotherapy for patient with colon cancer. We conducted this 
      meta-analysis to investigate the role of targeted agents in the adjuvant 
      treatment of colon cancer. We searched PubMed, MEDLINE, EMBASE, and the Cochrane 
      Library databases. We included phase III trials with the data of disease-free 
      survival (DFS) and adverse events (AEs) of adjuvant treatment with targeted 
      agents. From 5 eligible studies, a total of 9,991 patients with resected colon 
      cancer were included in the meta-analysis of hazard ratio (HR) for 3-year DFS and 
      odds ratio (OR) for grade 3 or higher AEs. The addition of targeted agents showed 
      no improvement of 3-year DFS, compared to standard adjuvant chemotherapy alone 
      (HR = 1.04 [95% confidence interval (CI), 0.96-1.13], P = 0.31). In the subgroup 
      analysis according to the type of targeted agents, neither bevacizumab (HR = 1.03 
      [95% CI, 0.88-1.21], P = 0.72) nor cetuximab (HR = 1.11 [95% CI, 0.94-1.31], P = 
      0.22) was associated with improvement of DFS. Moreover, targeted agents 
      significantly increased grade 3 or higher AEs (OR = 1.73 [95% CI, 1.21-2.46], P = 
      0.003) and treatment-related death (OR = 2.15 [95% CI, 1.16-3.99], P = 0.02). In 
      conclusion, this meta-analysis demonstrates that the addition of targeted agents 
      to standard adjuvant chemotherapy results in no improvement of DFS with increased 
      severe AEs and treatment-related death in patients with resected colon cancer.
FAU - Kim, Bum Jun
AU  - Kim BJ
AD  - Department of Internal Medicine, Division of Hemato-Oncology, Kangnam Sacred 
      Heart Hospital, Hallym University Medical Center, Hallym University College of 
      Medicine, Seoul, Republic of Korea.
FAU - Jeong, Jae Ho
AU  - Jeong JH
AD  - Center for Colorectal Cancer, Research Institute and Hospital, National Cancer 
      Center, Goyang-si, Republic of Korea.
FAU - Kim, Jung Han
AU  - Kim JH
AD  - Department of Internal Medicine, Division of Hemato-Oncology, Kangnam Sacred 
      Heart Hospital, Hallym University Medical Center, Hallym University College of 
      Medicine, Seoul, Republic of Korea.
FAU - Kim, Hyeong Su
AU  - Kim HS
AD  - Department of Internal Medicine, Division of Hemato-Oncology, Kangnam Sacred 
      Heart Hospital, Hallym University Medical Center, Hallym University College of 
      Medicine, Seoul, Republic of Korea.
FAU - Jang, Hyun Joo
AU  - Jang HJ
AD  - Department of Internal Medicine, Division of Gastroenterology, Dongtan Sacred 
      Heart Hospital, Hallym University Medical Center, Hallym University College of 
      Medicine, Hwasung, Republic of Korea.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use
MH  - Chemotherapy, Adjuvant
MH  - Clinical Trials, Phase III as Topic
MH  - Colonic Neoplasms/*drug therapy/mortality/pathology
MH  - Humans
MH  - *Molecular Targeted Therapy
MH  - Odds Ratio
MH  - Proportional Hazards Models
MH  - Treatment Outcome
PMC - PMC5458193
OTO - NOTNLM
OT  - adjuvant treatment
OT  - bevacizumab
OT  - cetuximab
OT  - colon cancer
OT  - targeted agent
COIS- CONFLICTS OF INTEREST All authors have declared no competing interest.
EDAT- 2017/04/19 06:00
MHDA- 2018/03/27 06:00
PMCR- 2017/05/09
CRDT- 2017/04/19 06:00
PHST- 2017/02/13 00:00 [received]
PHST- 2017/03/02 00:00 [accepted]
PHST- 2017/04/19 06:00 [pubmed]
PHST- 2018/03/27 06:00 [medline]
PHST- 2017/04/19 06:00 [entrez]
PHST- 2017/05/09 00:00 [pmc-release]
AID - 16091 [pii]
AID - 10.18632/oncotarget.16091 [doi]
PST - ppublish
SO  - Oncotarget. 2017 May 9;8(19):31112-31118. doi: 10.18632/oncotarget.16091.